Prosecution Insights
Last updated: April 19, 2026

Examiner: RAO, PADMAJA S

Tech Center 1600 • Art Units: 1627

This examiner grants 71% of resolved cases

Performance Statistics

71.2%
Allow Rate
+11.2% vs TC avg
179
Total Applications
+40.4%
Interview Lift
998
Avg Prosecution Days
Based on 118 resolved cases, 2023–2026

Rejection Statute Breakdown

2.3%
§101 Eligibility
17.2%
§102 Novelty
32.8%
§103 Obviousness
25.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18551699 NOVEL CYCLOPENTA[C]PYRROL NEGATIVE ALLOSTERIC MODULATORS OF NR2B Non-Final OA Novartis AG
18325655 R-MDMA CRYSTAL FORMS Non-Final OA Mind Medicine, Inc.
17791110 A METHOD OF TREATMENT IN PREDISPOSED SUBJECTS FOR LMNA-RELATED DILATED CARDIOMYOPATHY Non-Final OA The Board of Trustees of the Leland Stanford Junior University
17291055 COMPOSITIONS AND METHODS USING A COMBINATION OF CURCUMIN AND AN OMEGA-3 FATTY ACID FOR CELLULAR ENERGY Non-Final OA SOCIETE DES PRODUITS NESTLE S.A.
16966263 ANALGESIC AGENT AND SEDATIVE AGENT Non-Final OA THE UNIVERSITY OF TOKYO
18043163 HYDROXYNORKETAMINE COMPOUNDS AND METHODS OF USE THEREOF Non-Final OA THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF VETERANS AFFAIRS
18280531 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA Non-Final OA ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
17799638 NOVEL TDZD ANALOGS AS AGENTS THAT DELAY, PREVENT, OR REVERSE AGE-ASSOCIATED DISEASES AND AS ANTI-CANCER AND ANTILEUKEMIC AGENTS Non-Final OA BIOVENTURES, LLC
18282219 POLYHYDROXYLATED INDOLIZIDINE AND PYRROLIZIDINE DERIVATIVES AND USES THEREOF Non-Final OA Academia Sinica
18269122 SMALL MOLECULE DEGRADERS OF PHOSPHATIDYLINOSITOL-5-PHOSPHATE 4-KINASE TYPE 2 AND USES THEREOF Non-Final OA CORNELL UNIVERSITY
18746815 METHODS OF TREATMENT OR PREVENTION OF ACUTE BRAIN OR NERVE INJURIES Non-Final OA Annovis Bio, Inc.
18268469 6-SUBSTITUTED INDOLE COMPOUNDS Non-Final OA Gilead Sciences, Inc.
18566176 SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE Non-Final OA VERTEX PHARMACEUTICALS INCORPORATED
18328388 Method and Composition for Treating Epilepsy Final Rejection Lipocine Inc.
18027190 ASTROCYTIC TRPA1 CHANNEL INHIBITION AS A NOVEL NEUROPROTECTIVE THERAPEUTIC TARGET IN THE PRODROMAL PHASES OF ALZHEIMER'S DISEASE Final Rejection INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
18557852 PKC-Theta Modulators Final Rejection Celgene Corporation
18398201 NITROGEN-CONTAINING POLYCYCLIC AROMATIC COMPOUND, and PREPARATION METHOD AND APPLICATION THEREOF Non-Final OA Hebei University of Science & Technology
18395241 ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF Non-Final OA Pliant Therapeutics, Inc.
18561111 PHARMACEUTICALLY ACCEPTABLE SALT OF PYRAZOLOHETEROARYL DERIVATIVE AND CRYSTAL FORM THEREOF Non-Final OA SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
17770686 USE OF IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUNDS FOR PREVENTION, ALLEVIATION, OR TREATMENT OF COGNITIVE DISORDERS, OR FOR IMPROVING COGNITIVE FUNCTION Non-Final OA SK BIOPHARMACEUTICALS CO., LTD.
17769323 COMPOUNDS FOR TARGETED DEGRADATION OF CARRIER PROTEINS AND USES THEREOF Non-Final OA CeMM - Forschungszentrum für Molekulare Medizin GmbH
18289399 PHARMACEUTICAL COMPOSITION FOR USE IN TREATING CEREBRAL INFARCTION Non-Final OA Corxel Pharmaceuticals Hong Kong Limited
18289467 MODULATORS OF TREX1 Non-Final OA Constellation Pharmaceuticals, Inc.
18288455 MODULATORS OF TREX1 Non-Final OA Constellation Pharmaceuticals, Inc.
18262459 CRYSTAL FORM OF ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD FOR CRYSTAL FORM, AND USE OF CRYSTAL FORM Non-Final OA XIZANG HAISCO PHARMACEUTICAL CO., LTD.
18556499 TREATMENT OF HYPERAMMONEMIA Non-Final OA BIOCODEX
18371093 Salts of Viloxazine Non-Final OA Apotex Inc.
18272697 AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL Non-Final OA The University of Liverpool
18255816 Cannabidiol for the Treatment of Refractory Seizures Non-Final OA ZYNERBA PHARMACEUTICALS, INC.
18273574 Pharmaceutical Products Based on Cannabinoid Acid Esters Non-Final OA EVANGELOS DADIOTIS

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month